A Crossover Study of Prolactin Changes Associated With Risperidone and Olanzapine
J Clin Psychiatry 2006;67:1470-1471 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: We read with interest the recent article by Melkersson1 that described the differential effect on prolactin elevation in schizophrenic patients treated with clozapine (none of the patients had elevated prolactin), olanzapine (24% of the patients had elevated prolactin), and risperidone (89% of the patients had elevated prolactin). Previous head-to-head clinical trials have revealed similar results.2–5 However, these comparison studies might be limited by the individual variation in endocrine profiles, demographic variables such as age and gender, and concomitant medication use.6,7